Intrasense H1 revenue slides 59.3% to EUR 646,000

PUBT · 3d ago
Intrasense H1 revenue slides 59.3% to EUR 646,000
  • Intrasense reported H1 2026 revenue down 59.3% to EUR 646,000 versus H1 2025.
  • Decline tied to delayed renewals for several maintenance contracts, plus timing shifts in license orders.
  • All H1 revenue came from the Myrian business, which is in a disposal process announced on July 1, 2026.
  • DUonco Pancreas obtained Japanese regulatory marking weeks ago; product had received FDA Breakthrough Device status in 2025.
  • DUonco Unity in late-stage development; CE marking expected in Q3 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intrasense SA published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.